FOY 251 free base
Based on 2 publication(s) in Google Scholar
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor. FOY 25 free base inhibits SARS-CoV-2 infection in cells assay.
For research use only. We do not sell to patients.
- CAS No.: 71079-08-8
- Formula: C16H15N3O4
- Molecular Weight:313.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) FOY 251 free base
More
Biological Activity
Description
IC50 & Target
Proteinase[1]
In Vitro
FOY 251 free base represents a dose-dependent inhibition of equivalent current in M-1 cells[2].
FOY-251 free base inhibits the proteolytic activity of prostasin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 71079-08-8
-
Molecular Weight 313.31
-
Formula C16H15N3O4
-
SMILES
O=C(O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Res Sq
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. [Abstract]2024 Nov 21:rs.3.rs-5454588. PMID: 39606435
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. K Beckh, et al. Elimination of the Low-Molecular Weight Proteinase Inhibitor Camostate (FOY 305) and Its Degradation Products by the Rat Liver. Res Exp Med (Berl). 1987;187(6):401-6. [Content Brief]
[2]. Ai Maekawa, et al. Camostat Mesilate Inhibits Prostasin Activity and Reduces Blood Pressure and Renal Injury in Salt-Sensitive Hypertension. J Hypertens . 2009 Jan;27(1):181-9. [Content Brief]
[3]. Markus Hoffmann, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv. 2020 Aug 5;2020.08.05.237651. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FOY 251 free base Related Classifications
HY-19727 Related Classifications
Powered by Bioz